Floatz logo

Dotarem

Hepatic Cell Carcinoma

Massachusetts General HospitalActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Hepatic Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Afp Specific T Cell Receptor T Cells
Shanghai Ruiliyuan Biotechnology Co., Ltd.
Phase 1CC
HepaSphere Microspheres
Assiut University
Early Phase 1C
Gadobutrol
Massachusetts General Hospital
N/AD

Same molecule, other indications

Dotarem is also rated in:

early-onset autosomal dominant Alzheimer diseaseDormant
CC
Indicative ·
41 / 100
View asset →
Liver CirrhosisDormant
D
Indicative ·
30 / 100
View asset →
Portal HypertensionDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →